In the MGB Registry, obese individuals without prior CVD but with obstructive CAD on #CoronaryCTA had a similar risk of MACE as those in the #SelectTrial placebo group (pts w/ established CVD). 🫀 Grateful for the guidance of my mentor @RonBlankstein and our @BWHCVImaging team!

Honored to be named one of the 40 Under 40 Public Health Catalysts by the @BostonCongress. Deeply grateful to my team @BWHCVImaging and to my mentor @RonBlankstein for his support and guidance. Excited to keep pushing public health and CV science forward! https://t.co/pbCeORwTyH

Excited to share our @JACCJournals #JACCIMG paper led by ⭐️@Bweber04 on AI detection of CAC on chest CT among 2,546 individuals with IMID (SLE/RA/Psoriasis) who did not have hx of ASCVD ~50% had CAC --> most not on statin! ➡️Over 8 yrs, AI CAC provided robust a/w MACE + ACM

On behalf of senior author @gregorymmarcus and trial team: Honored to present the late-breaking clinical trial DECAF at #AHA25 today In contrast to conventional wisdom, coffee ☕️resulted in less AF #afib compared to abstinence! #SimPub @JAMA_current https://t.co/26K8Rn6jfU

🚨 Don’t miss this session at #AHA25! 🧠 AI-Plaque Analysis: The Paradigm Shift in CAD Management 🕒 Sunday, Nov 9 | 3:15–4:00 PM (CT) 📍 Heart Theater 1 Excited to learn from Dr. @RonBlankstein, Dr. Seth Martin, and Dr. @FaRodriguezMD.

Fabulous presentations by Vesalius Discussant ⁦@PamelaBMorris⁩ & by trial presenter Dr. Erin Bohula!

Late breaking #LBTC session 1 with focus on novel therapies in severe hypertriglyceridemia . Core 1TIMI72a and Core 2 TIMI 72b showing incredible promise for Olezarsen in SHTG reduction and prevention of pancreatitis ARR 32% @AHAScience #AHA2025 .

#CVPrevention highlights from @AHAScience: VESALIUS-CV trial takes PCSK9 inhibition beyond secondary prevention: Can evolocumab prevent first CV events in high-risk patients without prior MI or stroke? Design: N = 12,257 stable, high-CV-risk pts w/ no prior MI or stroke -

@rblument1 presenting at #AHA25 on the intensity & timing of LDL lowering 🫀elevated LDL exposure time matters 🫀risk scores don’t go young enough- waiting to 40 to treat may be too late 🫀don’t wait: cross the line early @CiccaroneCenter @MichaelJBlaha @SethShayMartin

Beyond stenosis: Integrating coronary inflammation and plaque detection in advanced cardiac care, with Dr. Charalambos Antoniades @CaristoHeart AI-enhanced CCTA (FAI Score & CaRi-Heart): 🔹Quantifies coronary inflammation 🔹Refines risk prediction 🔹Can reduce MACE by ~30% #AHA25

🫀#AHA25 #VESALIUS In high CV-risk pts w/o prior MI or stroke, adding evolocumab to lipid-lowering therapy: - LDL-C ↓ to median 45 mg/dL (1.16 mmol/L) - 25%↓ 3-P MACE | 19%↓ 4-P MACE - Consistent benefit across subgroups (incl. diabetes) - 27%↓ CVdeath/MI/stroke | 36%↓ MI

Honored to serve as a judge alongside these amazing mentors! Thank you to the CVRI team, and congratulations to all the presenters, you did a fantastic job today! #AHA25 ❤️

SIMULTANEOUS PUBLICATION AT #AHA25 🔥 First-in-human study of TN-201, an AAV9 gene replacement therapy in MYBPC3-associated hypertrophic cardiomyopathy Explore initial safety, pharmacodynamic, & imaging results from MyPEAK-1 https://t.co/2Oyn0jvSXu #CVD #CardiovascularResearch

🤖 Happening Now at #AHA25! 🫀 The Black Box of Opportunities: AI in CV Research and Medicine, moderated by Dr. @JHaimovichMD with Dr. @Donnakarnett, Dr. @al_zaiti, and Dr. Antonis Armoundas Great talk exploring how #AI and #ML are transforming CV care and research.

#AHA25 I wish this talk by Dr. Clyde Yancy @NMHheartdoc was available to every #EarlyCareer doctor around the🌍 Leadership isn’t just about titles, it’s about traits and tools. 🔹Gratitude, geneRosity, humIlity & crisis managemenT 🔹Resilience, Equanimity, Anchors & Perseverance

💡 Early Career, Big Impact at #AHA25! Inspiring AHA Early Career Day Opening by Dr. Umberto Campia @u_campia and @NancyatHeart 🫀 Don’t miss the chance to connect, learn, and grow at the #AHA25 early career sessions and networking events. 💬✨ #CardioTwitter #EarlyCareer

🧬 @drjamesware at #AHA25: “Leveraging Polygenic Risk Scores in HCM: Is More the Merrier?” 🔹 Polygenic contribution to HCM ≈30% 🔹 PRS predicts disease, outcomes & therapy response 🔹 PRS helps stratify patients and relatives: expressivity and penetrance #AHA25 #cardiotwitter

🧒 “Children are not small adults.” Great talk by Dr. Joseph Rossano on Pediatric HCM: Who, What, When, Where, Why.🫀In children: - HCM arises from diverse etiologies - Sarcomeric HCM often have a more severe phenotype #AHA25 #CardioTwitter #HCM #PediatricCardiology

🧬 Happening now at #AHA25! “Impact of Genetics on the Family - from Mendelian to Polygenic” is underway, starting with Dr. Jolanda van der Velden discussing how insights from the bench are transforming our understanding of HCM #AHA25 #CardioTwitter #Genetics

Excited to share that I’m one of the #AHA25 Social Media Ambassadors! I’ll be covering highlights from the @AHAScience #AHA25 Scientific Sessions in New Orleans, focusing on preventive cardiology, imaging, and innovative approaches to cardiovascular risk reduction.

You don’t want to miss @Bweber04 ‘s amazing talk! @ASPCardio @nationallipid @society_eas